Friday 3 September 2004
12:00-13:15
REGISTRATION (Sir William Wells Atrium)
13:45 Opening Remarks (Peter Samuel Hall)
Session 1: Control of hyperparathyroid hormone and maintenance of calcium and phosphate balance (14:00-16:10hrs)
J Cunningham, London, UK
Are all Vitamin D analogues equal in the treatment of hyperparathyroidism?
WS Goodman, Los Angeles, USA
Can calcium sensor receptor agonists improve the long-term medical management of renal hyperparathyroidism?
T Drüke, Paris, France
Does the use of Renagel reduce both vascular calcification and atheroembolic disease?
A Hutchison, Manchester, UK
Is lanthanum carbonate an effective and safe phosphate binder for end stage uraemia?
G Coen, Rome, Italy
Renal osteodystrophy in the non-calcium phosphate binder and calcium receptor agonist era
Session 2: Can haemodiafiltration improve the treatment and survival of patients with end stage renal failure? (16:40-18:20hrs)
E Spalding, Glasgow, UK
Comparison of b 2M and phosphate clearances during intermittent haemodiafiltration and haemodialysis
R Ward, Louisville, USA
The effect of haemodiafiltration on uraemic toxin removal
M Fischbach, Strasbourg, France
The effect of daily haemodiafiltration on patient morbidity and mortality
B Canaud, Montpellier, France
Does haemodiafiltration offer reduced patient morbidity and increased survival?
WELCOME RECEPTION
Saturday 4 September 2004
Session 3: Do the current peritoneal dialysis solutions cause interperitoneal inflammation and premature technique failure? (08:45-11:15hrs)
S Davies, Stoke-on-Trent, UK
Can peritoneal dialysis be a long-term treatment option?
A Weislander, Lund, Sweden
Do peritoneal dialysis solutions lead to peritoneal damage and premature therapy failure?
N Lameire, Ghent, Belgium
The role of nitric oxide on peritoneal blood flow and leukocyte-endothelial interactions
O Devuyst, Louvain-la-Neuve, Belgium
The role of intraperitoneal nitric oxide in small solute transport and intraperitoneal inflammation
N Topley, Cardiff, UK
Is it possible to control and improve resolution of intraperitoneal inflammation?
Session 4: Cardiovascular risk in end-stage renal failure. (13:45-16:40hrs)
P Vallance, London, UK
Endothelial dysregulation in uraemia and the impact of dialysis
G London, Fleury-Mérogis, France
Medial arterial calcification and left ventricular hypertrophy in the dialysis population
D Wheeler, London, UK
Can lipid lowering agents improve cardiovascular risk in the end-stage renal failure patient?
P Kalra, Manchester, UK
Does angioplasty and/or stenting of macrovascular atheromatous renal arterial disease prevent further deterioration of renal failure?
G Bernstock, London, UK
The role of the purinergic nervous system in the kidney
R Unwin, London, UK
Clinical role of purinergic nervous system
CONFERENCE DINNER
Sunday 5 September 2004
Session 5: The management of patients with hepato-renal failure (09:00-10:40hrs)
K Moore, London, UK
The pathophysiology of the hepato-renal syndrome
J Wendon, London, UK
Optimum medical management of hepato-renal syndrome
R Jalan, London, UK
Does MARS therapy improve patient outcomes in hepato-renal and acute liver failure?
Sauer, Berlin, Germany
The role of bioartificial liver support systems in the treatment of liver failure.
11:10-11:50hrs KEYNOTE LECTURE and ISBP Prize Award
Professor Sir Peter Morris, President, Royal College of Surgeons, London
TRANSPLANTATION: THE PAST, THE PRESENT, AND THE FUTURE
Session 6: When should dialysis treatment be initiated? (13:45-15:50hrs)
T Golper, Nashville, USA
DOQI guidelines for initiation of renal replacement therapy
R Greenwood, Stevenage, UK
Lessons from the DOPS study on initiation of haemodialysis in Europe and the USA
E Boeschoten, Amsterdam, The Netherlands
Is patient survival affected by early, compared to late start, or is treatment modality more important in predicting patient outcomes?
A Burns, London, UK
Does conservative non-dialysis management necessarily lead to reduced patient survival for the older patient?
15:50-16:50 DEBATE
K Farrington, Stevenage, UK, and T Golper, Nashville, USA
Patients need individualisation of treatment and not rigid guidelines laid down by Standards Committees
16:50 Closing remarks
